UNBS 5162

Drug Profile

UNBS 5162

Latest Information Update: 04 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unibioscreen
  • Developer Drais Pharmaceuticals; Unibioscreen
  • Class Antineoplastics; Cytostatics; Naphthalimides
  • Mechanism of Action Angiogenesis inhibitors; Chemokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 04 Mar 2010 UNBS 5162 is still in phase I development
  • 24 Oct 2008 Pharmacodynamics data from a preclinical trial in animal models of human cancers presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
  • 18 Sep 2008 Phase-I clinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top